Comparative Pharmacology
Head-to-head clinical analysis: CYCLOCORT versus HYTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOCORT versus HYTONE.
CYCLOCORT vs HYTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
Hydrocortisone (topical) binds to glucocorticoid receptors, activating anti-inflammatory proteins and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
Topical: Apply cream or ointment to affected area 2-4 times daily. Limit treatment area to less than 50% of body surface area. Maximum duration: 2 weeks unless directed by physician.
None Documented
None Documented
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
30–60 minutes (terminal elimination half-life; short duration requires frequent dosing)
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Renal (primarily as metabolites; ~25% as unchanged drug) and biliary/fecal
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid